Ct value Log concentration miR-375 miR-221 Supplementary Figure S1
Supplementary Figure S2 T-Bil CA19-9 AMY miR-221 concentration (amol/μl)
VariablesPatients (n=47) miR-221 Concentration (amol/μ l ) p-value a Age (year)mean (range)67 (42-84) ≤6516( 34.0% )3.31E ≥6631( 66.0% )4.29E-02 Sex Male 27( 57.4% )4.10E Femal20( 42.6% )4.29E-02 Histopathology Adenocarcinoma 42( 89.4% )4.38E Others5( 10.6% )2.56E-02 Location Ph34( 72.3% )4.15E Pb/Pt13( 27.7% )3.44E-02 Depth of invasion T0/1/27( 14.9% )2.87E T3/440( 85.1% )4.17E-02 Lymph node metastasis Negative17( 36.2% )3.71E Positive30( 63.8% )4.27E-02 Distant metastasis Negative38( 80.9% )3.42E Positive9( 19.1% )6.08E-02 Stage 0- Ⅱ A 16( 34.0% )3.54E Ⅱ B- Ⅳ 31( 66.0% )4.23E-02 Treatment Resectable37( 78.7% )3.47E Non-resectable10( 21.3% )5.75E-02 Characteristics and plasma miR-221 concentrations of 47 consecutive PCa patients NOTE. Significant values are in boldface type. a P values are from the Mann-Whitney U-test and were considered significant at Supplementary Table S1
Supplementary Table S2 Plasma miR-221 concentration (amol/μl) SamplenMean95% CI b p-value c Pancreatic cancer p < Benign tumor a p = Normal control a Five IPMNs, 2 serous cystadenomas, and 2 pancteatitis tumors were included in benign tumors. b 95% confidential interval c Plasma concentrations of each group were compared with those of normal controls by Mann-Whitney U test. Differential expression pattern of plasma miR-221 in patients with pancreatic, pancreatic benign tumors, and normal controls
Plasma miR-221Tumor miR-221 High plasma miR-221 cases a Concentration (amol/μl)Tumor expressionmiR-221/U6B ratio 11.94E-01high E-01high E-02high E-02high E-02high E-02high1.34 Rate reflecting tumor dynamics100% b a Cut-off value of plasma miR-221 concentrations in healthy volunteers (mean+2SD): 4.047E-02 amol/μl b Cut-off value of miR-221/U6B ratios in normal pancreatic tissues (median): 1.00 Relationship between miRNA-221 in plasma and pancreatic cancer tissues Supplementary Table S3